26 27 28 29 30 31 32 2 33 Abstract 34 Breast cancer drug resistance is the leading cause of cancer-related mortality in women, and 35 triple negative breast cancer (TNBC) is the most aggressive subtype, affecting African American 36 women more aggressively compared to Caucasians. Of all cancer-related deaths, 15 to 20% are 37 associated with inflammation, where proinflammatory cytokines have been implicated in the 38 tumorigenesis process. The current study investigated the effects of the polyphenolic compound 39 butein (2′,3,4,4′-tetrahydroxychalcone) in cell proliferation and survival, as well as its modulatory 40 effect on the release of proinflammatory cytokines in MDA-MB-231 (Caucasian) and MDA-MB-41 468 (African American) TNBC cell. Results showed that butein decreased cell viability in a time 42 and dose-dependent manner and after 72-h of treatment, cell proliferation rate was reduced in 43 both cell lines. In addition, butein presented higher potency in MDA-MB-468, exhibiting anti-44 proliferative effects in lower concentrations. Apoptosis assays demonstrated that butein increased 45 apoptotic cells in MDA MB-468, showing 90% of the analyzed cells in the apoptotic phase, 46 compared to 54% in MDA-MB-231 cells. Additionally, butein downregulated both, protein and 47 mRNA expression of CCL2 proinflammatory cytokine and IKBKE in Caucasian cells, but not in 48 African Americans. This study demonstrates butein potential in cancer suppression showing a 49 higher cytotoxic, anti-proliferative, and apoptotic effects in African Americans, compared to 50 Caucasians TNBC cells. It also reveals the butein inhibitory effect on CCL2 expression with a 51 possible association with IKBKE downregulation in MDA-MB-231 cells only, indicating that
67
In Asian countries, butein has been used in herbal medicine formulations and as a food additive 68
[8]. Also, butein exhibits a variety of pharmacological properties including anti-inflammatory, 69 antioxidative, and antimicrobial activities [9, 10] .
70
In cancer studies, butein induced apoptosis in colon adenocarcinoma [11] , breast cancer 71 cells [12, 13] , hepatocellular carcinoma [14, 15] , and prostate cancer cells [16, 17] . Butein treatment 72 also inhibited invasion and migration of bladder [18] , pancreatic, and breast cancer cells [19] , as 73 well as in hepatocellular carcinoma [20] . Breast cancer cell studies showed that butein inhibited 74 ER + MCF-7 cells growth [12] , and blocked CXCL12-induced migration and invasion of human 75 epidermal growth factor receptor 2 positive (HER2 + ) in SKBR-3 breast cancer cells by repressing 76
NFқB-dependent CXCR4 expression [19] . Moreover, the compound induced apoptosis in MDA-
77
MB-231, though ROS generation and ERK1/2 and p38MAPK dysregulation [13] . These findings 78
show butein potential as a promising chemopreventive and chemotherapeutic potential agent [21] .
79
The high prevalence and increasing drug resistance of breast cancer is the leading cause 80 of cancer-related mortality in women [22] . In 2018, there was an estimated number of 266,000 81 new cases of invasive breast cancer to be diagnosed in the U.S., alongside 64,000 new cases of 82 non-invasive breast cancer [23] . Breast cancer is classified into three major therapeutic subtypes: 83 estrogen and/or progesterone receptor-positive (ER + , PR + ), HER2 + , and triple-negative breast 84 cancer (TNBC) (lacking expression of ER, PR, and HER2) [24, 25] . TNBC covers 15 to 20% of all 85 breast cancers [26] , and it is linked to a worse prognosis, increased incidence of metastasis to 86 lung, liver, and brain, early relapse after treatment, and lower survival rate compared to other 87 breast cancer subtypes [27] . TNBC is more common in African American women compared to 88 other ethnic groups [28, 29] and it is associated with a worse clinical outcome, and it presents 89 higher mortality [27, 30] . TNBC subtypes respond differently to the treatment, challenging, even 90 more, the development of target therapy with certain chemotherapeutics that may be safe and 91 effective at the same time [25, 31] .
92
In addition to breast cancer heterogeneity, it is also known that 15 to 20% of all cancer- Data analysis was performed using GraphPad Prism (version 6.07) (San Diego, CA, USA).
247
All data points are expressed as the mean ± S.E.M. from at least 2 independent experiments.
248
For the viability studies, the IC 50 was determined by nonlinear regression with R 2 best fit and 249 lowest 95% confidence interval. Statistically significant differences between different groups in 250 the experiments was assessed using a one-way ANOVA, followed by Dunnett's multiple 
263
MB-468 cells (Fig 1) .
265
The cytotoxic effect of butein was examined by incubating both cell lines with butein for 
269
Further decrease in the cell viability was also measured at 72-h incubation period, reducing IC 50 s 270 to 1.11 and 1.78 µM in MDA-MB-231 and MDA-MB-468, respectively (Figs 2A and B) . growth and showed its potency as an anti-proliferative agent (Figs 3A and B) .
280
The apoptotic effect of butein was determined by flow cytometry using Annexin V-FITC/PI 281 staining in cells exposed to butein for 24 h. In MDA-MB-231 cells, there was a significant increase (Figs 5A and B) . These results demonstrate that butein was more effective 288 in inducing apoptosis in African American compared to Caucasians in TNBC cells. In order to evaluate the relationship between the anti-cancer effects of butein treatment 296 and the inhibitory effect on pro-cytokines release, a semi-quantitative analysis using human 297 antibody arrays was performed (Figs 6A and 7A) . The results showed that TNF-α induced the 298 upregulation of three specific cytokines: chemokine (C-C motif) ligand 2 (CCL2/MCP-1), insulin-299 like growth factor-binding protein 1 (IGFBP1), and interleukin-6 (IL-6) in MDA-MB-231 cells, 300 although CCL2 was the only one upregulated in its counterpart MDA-MB-468 (Figs 6B and 7B) .
301
Butein presented a different effect in the two cell lines examined, inhibiting CCL2 expression in Figs 8A and B) . (Figs 9A and B) . (Figs 10A and B) . These results indicate that the changes in CCL2 expression 356 caused by butein at the transcriptome level, follow the same pattern observed at the protein level. (Figs 11A and B) . These data demonstrate that IKBKE may be one of the NFқB signaling 374 genes implicated in the TNF-α-induced CCL2 release and its down-regulation by butein. 
391
However, there is no data comparing the effect of this compound in racially different TNBC cells.
392
The current study shows butein anticancer properties in TNBC cells, specifically MDA-MB-231 393 and MDA-MB468, representing Caucasians and African Americans. Overall the results obtained 394 in our study provide more evidence for butein cytotoxicity towards both cell lines. However, the 395 compound highly impacted MDA-MB-468 cells, in which lower concentrations were more effective 396 in reducing cell viability (Figs 1, 2A and B) , and decreasing cell proliferation (Fig 3) . These data (Figs 4A and B; 5A and B) .
400
Proliferative and anti-apoptotic effects have been described to be associated with NFқB 
416
Considering that the association of chronic inflammation with infection and irritation may 417 promote environments that induce DNA lesions and tumor initiation [62], the current study 418 investigated butein ability to inhibit TNF-α-mediated release of proinflammatory cytokines. The
419
obtained findings in the current study show that butein attenuated the expression of CCL2, at 420 both protein and mRNA levels in MDA-MB-231, but not in MDA-MB-468 cells (Figs 8A and B, 9A   421  and B, 10A and B 
442
MB-468 cells is not associated with CCL2 regulation.
443
Our investigation showed that butein inhibitory effect on CCL2 expression in Caucasian 444 cells might be attributed to its ability to downregulate IKBKE mRNA expression (Fig 11 A and B) . 
445

457
In summary, the present investigation demonstrates butein potential in cancer (Figs 12 and 13) .
464
Therefore, the obtained findings indicate that butein might be a potential candidate in breast 465 cancer therapy targeting CCL2 in Caucasians and may also provide an explanation regarding the 466 poor response to therapy in African American patients with advance TNBC. 
